VEGFA and lung adenocarcinoma: The anti-VEGF-A antibody bevacizumab was shown to prevent BM in a lung adenocarcinoma mouse BM model [23], and the retrospective analysis of the AVAIL trial revealed a reduction of BM as first site of relapse with bevacizumab treatment [15].